Paying $55 million, Cephalon Inc. bought back the interest of two unaffiliated investors in a joint venture formed in December to put as much as $50 million into U.S. commercial efforts on behalf of Provigil for sleep disorders and Gabitril for epilepsy. (BioWorld Today) Read More
